MIEBO Drug Patent Profile

When do Miebo patents expire, and what generic alternatives are available?

Miebo is a drug marketed by Bausch And Lomb Inc and is included in one NDA. There are six patents protecting this drug.

This drug has one hundred and nine patent family members in sixteen countries.

The generic ingredient in MIEBO is perfluorohexyloctane. One supplier is listed for this compound. Additional details are available on the perfluorohexyloctane profile page.

DrugPatentWatch^® Generic Entry Outlook for Miebo

Miebo will be eligible for patent challenges on May 18, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 18, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for MIEBO

International Patents:	109
US Patents:	6
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Drug Prices:	Drug price information for MIEBO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for MIEBO
What excipients (inactive ingredients) are in MIEBO?	MIEBO excipients list
DailyMed Link:	MIEBO at DailyMed

See drug prices for MIEBO

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for MIEBO

Constraining patent/regulatory exclusivity:

NEW CHEMICAL ENTITY

NDA:

216675

Dosage:

SOLUTION/DROPS;OPHTHALMIC

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for MIEBO

Drug Class

Semifluorinated Alkane

US Patents and Regulatory Information for MIEBO

MIEBO is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on NEW CHEMICAL ENTITY.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes
Bausch And Lomb Inc	MIEBO	perfluorohexyloctane	SOLUTION/DROPS;OPHTHALMIC	216675-001	May 18, 2023		RX	Yes	Yes

International Patents for MIEBO

When does loss-of-exclusivity occur for MIEBO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Germany

Hong Kong

Japan

Malaysia

Mexico

Poland

Portugal

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering MIEBO around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2013314303
Australia	2013314370
Australia	2016219611
Australia	2017200907

MIEBO Market Dynamics, Revenue Growth, Patent Protection and Generic Entry Risk

Last updated: August 4, 2026

MIEBO, Bausch + Lomb’s perfluorohexyloctane ophthalmic solution, has become one of the company’s fastest-growing prescription products. U.S. sales reached approximately $211 million in 2024, compared with about $55 million during its partial 2023 launch period. The product addresses evaporative dry eye disease through direct reduction of tear-film evaporation rather than primarily suppressing ocular inflammation. Its commercial outlook depends on prescription conversion, payer access, repeat use, physician adoption and the timing of generic or competing ophthalmic products.

MIEBO received U.S. Food and Drug Administration approval on May 18, 2023, under NDA 214782. It is approved for the treatment of signs and symptoms of dry eye disease due to Meibomian gland dysfunction in adults. Bausch + Lomb markets the product in the United States, while the underlying technology originated with Novaliq GmbH. (U.S. Food and Drug Administration [FDA], 2023a; Bausch + Lomb, 2025a)

How large is the MIEBO market?

MIEBO operates in the prescription dry-eye market, which includes anti-inflammatory drugs, tear substitutes, secretagogues and products designed to stabilize the tear film.

The commercial target is particularly important because Meibomian gland dysfunction is a common cause of evaporative dry eye. MIEBO is positioned for patients whose symptoms are associated with lipid-layer dysfunction and excessive tear evaporation. The product does not require refrigeration and is administered as one drop in each affected eye four times daily. (FDA, 2023b)

Which products compete with MIEBO?

Product	Active ingredient or technology	Primary commercial position	Competitive relationship
MIEBO	Perfluorohexyloctane	Tear evaporation reduction; Meibomian gland dysfunction	Direct evaporative-dry-eye competitor
Restasis	Cyclosporine ophthalmic emulsion	Chronic ocular inflammation	Indirect and substitution competitor
Xiidra	Lifitegrast	Ocular inflammation and dry-eye symptoms	Indirect and substitution competitor
VEVYE	Cyclosporine ophthalmic solution 0.1%	Dry-eye disease and inflammation	New branded prescription competitor
Tyrvaya	Varenicline nasal spray	Stimulates natural tear production	Mechanistically distinct competitor
Generic cyclosporine products	Cyclosporine ophthalmic formulations	Lower-cost chronic therapy	Payer and formulary competitor
Artificial tears	Multiple lubricating agents	Symptomatic relief	Over-the-counter substitute

MIEBO’s principal differentiation is its nonaqueous, semifluorinated alkane formulation. The product is intended to spread across the ocular surface and reduce evaporation. The commercial proposition is strongest in patients with evaporative disease, inadequate response to lubricants or intolerance of anti-inflammatory treatments.

What were MIEBO’s sales and financial trajectory?

MIEBO generated approximately $211 million of net sales in 2024, compared with approximately $55 million in 2023. The 2023 figure reflected a limited launch period after FDA approval. On that basis, 2024 sales increased by roughly 280%.

Period	Approximate MIEBO sales	Commercial interpretation
2023	$55 million	Partial-year launch
2024	$211 million	Full-year expansion and prescription growth
2025 outlook	Continued growth expected	Dependent on access, adherence and competitive launches

Bausch + Lomb has described MIEBO as a major growth driver within its prescription pharmaceutical portfolio. The product’s revenue contribution remains small relative to the company’s overall sales, but its growth rate is materially higher than that of mature ophthalmic products. Bausch + Lomb reported approximately $5.1 billion in total 2024 revenue. MIEBO therefore represented roughly 4% of company-wide sales, while accounting for a larger share of incremental prescription-pharmaceutical growth. (Bausch + Lomb, 2025a)

What is driving MIEBO prescription growth?

The main commercial drivers are:

1. Expansion of the U.S. ophthalmology and optometry sales effort.
2. Increased recognition of Meibomian gland dysfunction as a distinct disease mechanism.
3. Demand for a treatment directed at tear evaporation rather than only inflammation.
4. Repeat use in a chronic condition.
5. Potential use alongside anti-inflammatory dry-eye therapies.
6. Patient and physician preference for a non-preserved, topical ophthalmic product.

The principal constraints are the four-times-daily dosing schedule, branded-drug pricing, insurance coverage, prior authorization requirements and competition from established generic cyclosporine products.

When does MIEBO lose regulatory exclusivity?

MIEBO’s FDA approval date was May 18, 2023. If the product received five-year new chemical entity exclusivity, the expected regulatory exclusivity period runs through May 18, 2028. An abbreviated new drug application containing a Paragraph IV certification generally could not be filed before the fourth anniversary of approval, or May 18, 2027, subject to the specific FDA regulatory classification and applicable statutory provisions.

FDA milestone	Date
NDA approval	May 18, 2023
Four-year Paragraph IV filing threshold, if NCE exclusivity applies	May 18, 2027
Five-year NCE exclusivity expiration, if applicable	May 18, 2028
Earliest potential generic launch	Dependent on patent litigation, court findings and settlement terms

Regulatory exclusivity and patent protection are separate. The end of NCE exclusivity would permit certain ANDA filings, but it would not necessarily permit commercial launch if listed patents remain enforceable.

What patents protect MIEBO?

MIEBO’s intellectual-property position is based on patents covering perfluorohexyloctane and related perfluoroalkyl compounds, ophthalmic compositions, and methods of treating ocular-surface disorders. Novaliq GmbH is associated with the underlying technology, while Bausch + Lomb has commercial rights in the United States.

The relevant patent estate can include:

• Composition-of-matter patents covering perfluoroalkyl compounds.
• Ophthalmic formulation patents covering nonaqueous solutions.
• Method-of-use patents covering dry-eye treatment.
• Patents directed to Meibomian gland dysfunction and tear-film stabilization.
• Manufacturing and purification patents for pharmaceutical-grade perfluorohexyloctane.

What is the Orange Book status of MIEBO?

MIEBO is an NDA product and can receive Orange Book patent listings under FDA rules. The operative commercial question is not only whether a patent is listed, but also whether the patent claims the approved product, the active ingredient, the formulation or the approved method of use.

Orange Book listings can change through patent additions, corrections, delistings and expiration updates. The principal risk periods are therefore:

• The 2027-2028 period, when ANDA applicants may begin challenging MIEBO protection.
• The period after any listed patent expiration.
• Any litigation period triggered by a Paragraph IV notice.
• Any settlement date that permits an earlier generic launch.

MIEBO’s patent strength is likely higher for formulation and method-of-use claims than for a basic product concept alone. A generic applicant could attempt to design around claims directed to a particular concentration, excipient profile, dosing regimen or indication. Bausch + Lomb’s protection is stronger if the listed claims cover the product’s core composition rather than only a narrow use.

What Paragraph IV challenges and patent litigation affect MIEBO?

No material public MIEBO Paragraph IV litigation or generic settlement had been disclosed through the latest public company reporting available for the 2024 financial year. That status can change once ANDA applicants reach the statutory filing window.

A Paragraph IV challenge would create several possible outcomes:

Scenario	Commercial result
No challenge before patent expiration	Branded exclusivity continues until patent expiry
Paragraph IV notice with no lawsuit	Generic applicant may face a lower litigation barrier
Bausch + Lomb sues within 45 days	Automatic 30-month stay may apply, subject to statutory exceptions
Court upholds patents	Generic launch is delayed
Court invalidates or narrows patents	Earlier generic entry becomes possible
Settlement with licensed entry date	Market entry occurs on the agreed date

The absence of disclosed litigation is positive for near-term revenue visibility, but it does not eliminate later generic risk. High sales growth increases the economic incentive for ANDA applicants to challenge the product.

How strong is the MIEBO patent estate?

MIEBO has a stronger commercial protection profile than a product protected only by a single use patent because its value can be supported by multiple patent categories and regulatory exclusivity. The key question is claim breadth.

Strengths

• First FDA-approved product specifically positioned around perfluorohexyloctane.
• Differentiated mechanism for evaporative dry eye.
• Potential composition, formulation and method-of-use protection.
• Five-year regulatory exclusivity may delay ANDA filing until 2027.
• Chronic-use indication supports meaningful revenue during the protected period.

Weaknesses

• Dry-eye treatment has established branded and generic alternatives.
• Physicians can substitute therapies without waiting for a direct generic equivalent.
• Four-times-daily administration may limit adherence.
• Narrow formulation claims may be vulnerable to design-around strategies.
• The product is a small-molecule ophthalmic solution, not a biologic, so biosimilar barriers do not apply.

Does MIEBO face biosimilar risk?

No. MIEBO is not a biologic and does not use the biosimilar pathway. Future competition would most likely come through an ANDA for a generic equivalent or through competing branded ophthalmic products.

The practical threat is therefore generic substitution, not biosimilar substitution. A successful ANDA applicant could obtain pharmacy-level substitution depending on state law and payer policy. Branded alternatives such as VEVYE and Tyrvaya would compete through prescribing, formulary placement and sales promotion rather than automatic substitution.

What generic launch scenarios exist for MIEBO?

The most likely generic-entry scenarios are:

1. No early challenge: MIEBO retains branded share until the earliest relevant patent expiration.
2. Paragraph IV challenge followed by settlement: A generic receives a negotiated launch date before the last patent expiration.
3. Successful invalidity or non-infringement challenge: Generic entry occurs after litigation, potentially before 2030.
4. At-risk launch: A generic launches before final judgment, exposing the applicant to damages if the patents are upheld.
5. Authorized generic or branded-generic strategy: Bausch + Lomb or a partner launches a lower-priced version to defend volume.

For a chronic ophthalmic product, first-generic price erosion could be material, but the pace may be slower than for high-volume oral drugs because prescribing is concentrated among eye-care specialists and product switching can depend on clinical response.

How does MIEBO compare with Restasis, Xiidra and VEVYE?

MIEBO has a different clinical and commercial profile from Restasis and Xiidra. Restasis and Xiidra primarily compete in inflammatory dry eye, while MIEBO targets tear-film evaporation associated with Meibomian gland dysfunction.

Factor	MIEBO	Restasis	Xiidra	VEVYE
Mechanism	Reduces tear evaporation	Cyclosporine immunomodulation	Lifitegrast immunomodulation	Cyclosporine solution
Indication	Dry eye due to Meibomian gland dysfunction	Increased tear production in dry eye	Signs and symptoms of dry eye	Dry eye disease
Generic pressure	Future ANDA risk	High, with generic competition	Generic competition emerging	Limited early lifecycle
Dosing	Four times daily	Typically twice daily	Twice daily	Twice daily
Market position	Evaporative dry eye	Established chronic therapy	Established chronic therapy	Newer anti-inflammatory option

MIEBO can expand the dry-eye market by identifying patients who do not fit an inflammation-first treatment model. It can also be prescribed sequentially or concurrently with other therapies, although actual combination use depends on physician practice and payer restrictions.

What licensing deals support MIEBO?

Novaliq developed the perfluorohexyloctane technology. Bausch + Lomb entered into a licensing and commercialization relationship with Novaliq and later obtained commercial rights associated with the product. The transaction structure included upfront payments and potential milestone economics tied to development, regulatory approval and commercialization. (Bausch + Lomb, 2022)

The licensing arrangement gives Bausch + Lomb access to an internally differentiated product without originating the underlying molecule. It also creates economic obligations that can reduce the portion of product revenue retained as operating profit. The arrangement remains commercially attractive if MIEBO achieves sustained sales growth before generic entry.

What is the geographic coverage of MIEBO?

The U.S. is the principal commercial market disclosed in Bausch + Lomb’s public reporting. International expansion depends on country-specific approvals, reimbursement decisions and patent rights.

Geographic risks include:

• Different approval standards for ophthalmic products.
• Country-level pricing controls.
• Reimbursement delays.
• Patent term differences.
• Local generic and branded competition.
• Separate distribution and commercialization costs.

U.S. performance is therefore the main indicator of the product’s current commercial value. International launches could extend the revenue curve, but they are unlikely to offset a major U.S. generic event unless the product achieves broad multinational adoption.

Key Takeaways

• MIEBO generated approximately $211 million in 2024 sales after about $55 million in partial-year 2023 sales.
• Bausch + Lomb has positioned MIEBO as a growth product for evaporative dry eye and Meibomian gland dysfunction.
• The product competes mechanistically with lubricants and anti-inflammatory therapies, but it is not a direct clinical substitute for every dry-eye patient.
• If five-year NCE exclusivity applies, Paragraph IV filings could begin around May 18, 2027, with regulatory exclusivity extending to May 18, 2028.
• No material public Paragraph IV litigation or settlement had been disclosed through the latest 2024 reporting period.
• MIEBO is a small-molecule ophthalmic product and faces generic, not biosimilar, risk.
• Its patent value depends on the breadth and enforceability of composition, formulation and method-of-use claims.
• Revenue exposure is meaningful for Bausch + Lomb’s prescription portfolio but remains modest relative to total company sales.
• The key commercial inflection points are payer access, repeat prescribing, international expansion and the first ANDA challenge.

FAQs

Is MIEBO a steroid or an immunosuppressant?

No. MIEBO contains perfluorohexyloctane and is designed to reduce tear evaporation. It is not a corticosteroid, cyclosporine product or lifitegrast product.

Is MIEBO covered by Medicare?

Coverage depends on the specific Medicare Part D plan, formulary placement, prior authorization rules and patient eligibility. Coverage can differ substantially among plans.

Can MIEBO be used with Restasis or Xiidra?

The products have different mechanisms, and physicians may use them in sequence or combination. The FDA-approved labeling does not establish every possible combination regimen.

What company owns MIEBO?

Bausch + Lomb commercializes MIEBO. The underlying perfluorohexyloctane technology originated with Novaliq GmbH under a commercial licensing relationship.

What would cause MIEBO sales to decline before generic entry?

The main risks are payer restrictions, lower persistence caused by four-times-daily dosing, physician preference for cheaper generic therapies, competing branded dry-eye launches and weaker-than-expected differentiation in Meibomian gland dysfunction.

References

1. Bausch + Lomb Corporation. (2025a). Annual report for the fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.

2. Bausch + Lomb Corporation. (2022). Bausch + Lomb enters into agreement with Novaliq for NOV03 for dry eye disease. Company release.

3. U.S. Food and Drug Administration. (2023a). MIEBO approval letter, NDA 214782. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2023b). MIEBO prescribing information. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

DrugChatter Q&A for MIEBO

Miebo cost without insurance?
When will miebo patent expire?
Miebo drops cost in france today?
Where is the drug miebo produced?
Generic entry of miebo eye drop?